Nateglinide-d5

Nateglinide-d5

• CAS Number: 1227666-13-8
• UNSPSC Description: Nateglinide-d5 is a deuterium labeled Nateglinide. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K+ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus[1][2].
• Target Antigen: Dipeptidyl Peptidase; Potassium Channel
• Type: Isotope-Labeled Compounds
• Related Pathways: Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease
• Applications: Metabolism-protein/nucleotide metabolism
• Field of Research: Metabolic Disease
• Purity: 98.0
• Solubility: 10 mM in DMSO
• Smiles: O=C(O)[C@@H](CC1=C([2H])C([2H])=C([2H])C([2H])=C1[2H])NC([C@H]2CC[C@H](C(C)C)CC2)=O
• Molecular Weight: 322.45
• References & Citations: [1]Christopher J. Dunn, et al. Nateglinide. OFILE Drugs 2000 Sep: 60 (3): 6.|[2]Shiling Hu, et al. Interaction of nateglinide with KATP channel in h-cells underlies its unique insulinotropic action. European Journal of Pharmacology. 442 (2002) 163-171.|[3]Jian Luo, et al. Evaluating insulin secretagogues in a humanized mouse model with functional human islets. Metabolism. 2013 Jan;62(1):90-9.|[4]Duffy NA, et al. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1. Eur J Pharmacol. 2007 Jul 30;568(1-3):278-86.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C, 3 years (Powder)
• Clinical Information: No Development Reported